Comparative Pharmacology
Head-to-head clinical analysis: NESACAINE versus XYLOCAINE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: NESACAINE versus XYLOCAINE.
NESACAINE vs XYLOCAINE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Nesacaine (chloroprocaine) is an ester-type local anesthetic that blocks voltage-gated sodium channels in neuronal membranes, inhibiting the initiation and conduction of nerve impulses.
Lidocaine binds to and inhibits voltage-gated sodium channels in the neuronal membrane, stabilizing the membrane and preventing the initiation and conduction of nerve impulses, thereby producing local anesthesia.
Injectable local anesthetic: 1% or 2% solution, maximum dose 7 mg/kg (not to exceed 500 mg) with epinephrine, 4.5 mg/kg (not to exceed 300 mg) without epinephrine. Administer by infiltration or nerve block; may repeat at 30-minute intervals.
1-5 mg/kg (max 300 mg) local infiltration; epidural: 1-2% solution, 5-20 mL.
None Documented
None Documented
Terminal half-life: 40-60 minutes (rapidly metabolized by plasma pseudocholinesterase); clinical context: prolonged with hepatic dysfunction or atypical pseudocholinesterase
Terminal elimination half-life is approximately 1.5 to 2 hours in adults, prolonged to 2-3 hours in patients with hepatic impairment, and may exceed 5 hours in neonates or patients with heart failure.
Renal: 90-95% as unchanged drug and metabolites (predominantly 4-hydroxypropycaine); biliary/fecal: <5%
Hepatic metabolism (primarily by CYP1A2 and CYP3A4) to metabolites, mainly monoethylglycinexylidide (MEGX) and glycinexylidide (GX); less than 10% excreted unchanged in urine. Renal excretion of metabolites: MEGX (70-80%) and GX (10-20%). Biliary/fecal elimination is minimal.
Category C
Category C
Local Anesthetic
Local Anesthetic